Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment after at least one patient suffered heart failure.

The New York company hasn’t determined the cause or whether it is tied to the potential treatment, so it is examining all patients who took the drug.